<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017641</url>
  </required_header>
  <id_info>
    <org_study_id>199/14976</org_study_id>
    <secondary_id>NU-95LU1</secondary_id>
    <nct_id>NCT00017641</nct_id>
  </id_info>
  <brief_title>Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety of immune ablation with high-dose cyclophosphamide and anti-thymocyte&#xD;
      globulin followed by peripheral blood stem cell support in patients with systemic lupus&#xD;
      erythematosus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Patients receive cyclophosphamide IV over 1 hour for 2 doses. Patients&#xD;
      receive filgrastim (G-CSF) subcutaneously (SC) beginning 24 hours after completion of&#xD;
      cyclophosphamide and continuing until leukapheresis is complete. Leukapheresis continues&#xD;
      daily until target number of cells is harvested. CD 34+ cells are isolated from peripheral&#xD;
      blood stem cells (PBSC) in vitro.&#xD;
&#xD;
      Patients then receive cyclophosphamide IV over 1 hour on days -5 to -2, anti-thymocyte&#xD;
      globulin IV over 10 hours on days -4 to -2, and G-CSF SC beginning on day 0 and continuing&#xD;
      until blood counts recover. Patients undergo reinfusion of CD34+ PBSC on day 0.&#xD;
&#xD;
      Patients are followed weekly for 90 days, monthly for 1 year, and at 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2001</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>10</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CD34+ Peripheral Blood Stem Cell Reinfusion</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Diagnosis of systemic lupus erythematosus with 1 of the following malignant features:&#xD;
&#xD;
          -  Nephritis (WHO class III or IV)&#xD;
&#xD;
          -  Failed NIH short-course cyclophosphamide therapy&#xD;
&#xD;
          -  Vasculitis/immune complex deposition causing end organ signs or symptoms (e.g.,&#xD;
             cerebritis, transverse myelitis, pulmonary hemorrhage, cardiac failure, or renal&#xD;
             failure)&#xD;
&#xD;
          -  Hematologic cytopenias that are immune mediated and uncontrolled by conservative&#xD;
             measures with any of the following:&#xD;
&#xD;
        Transfusion-dependent anemia with untransfused hemoglobin less than 8 g/dL&#xD;
&#xD;
        Platelet count less than 40,000/mm3 (without transfusions)&#xD;
&#xD;
        Granulocyte count less than 1,000/mm3&#xD;
&#xD;
        Catastrophic anti-phospholipid syndrome&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF at least 35%&#xD;
&#xD;
          -  No lupus-induced myocarditis&#xD;
&#xD;
          -  No history of unstable angina&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV1/FVC at least 50% predicted&#xD;
&#xD;
          -  DLCO at least 50% predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No prior or concurrent malignancy except localized basal cell or squamous cell skin&#xD;
             cancer&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No medical illness that would preclude study&#xD;
&#xD;
          -  No psychiatric illness or mental deficiency that would preclude study&#xD;
&#xD;
          -  No known hypersensitivity to E. coli-derived proteins&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Traynor</last_name>
    <role>Study Chair</role>
    <affiliation>Northwestern Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2003</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>June 5, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>arthritis &amp; connective tissue diseases</keyword>
  <keyword>immunologic disorders and infectious disorders</keyword>
  <keyword>rare disease</keyword>
  <keyword>systemic lupus erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

